Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study

被引：0
|
作者：
Dirix, L. Y.
Romieu, G.
Provencher, L.
Grimes, D.
de Souzo, Viana L.
Paterson, A.
Mauriac, L.
Kirsch, A.
Pernas, S.
Miles, D. W.
机构：
[1] Oncol Ctr AZ St Augustinus Oncol, Antwerp, Belgium
[2] CRLCC Val Aurelle, Montpellier, France
[3] Hop St Sacrement, Quebec City, PQ, Canada
[4] Brisbane Haematol Oncol Clin, Auchenflower, Australia
[5] Hosp Canc Barretos, Barretos, Brazil
[6] Tom Baker Canc Clin, Calgary, AB, Canada
[7] Inst Bergonie, Bordeaux, France
[8] Onkol Schwerpunki Oskar Helene Heim, Berlin, Germany
[9] Inst Catala Oncol, Barcelona, Spain
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：285S / 285S
页数：1
相关论文
共 50 条
  • [31] Gemcitabine plus epirubicin plus taxol (GET) in metastatic breast cancer (MBC) patients (pts): A multicenter phase II study.
    Donati, S
    Gennari, A
    Conte, PF
    Cetto, GL
    Molino, A
    Crino, L
    Mazzoni, F
    Galligioni, E
    Mansutti, M
    ANNALS OF ONCOLOGY, 2000, 11 : 50 - 50
  • [32] A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) plus trastuzumab (H) plus docetaxel (0) versus Pla plus H plus D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).
    Xu, Binghe
    Li, Wei
    Zhang, Qingyuan
    Shao Zhimin
    Jia, Wang Xiao
    Li, Huiping
    Sun, Tao
    Yin, Yongmei
    Zheng, Hong
    Zhang, Hong
    Chan, Tiffanie
    Lei, Guiyuan
    Restuccia, Eleonora
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
    Chan, Stephen
    Romieu, Gilles
    Huober, Jens
    Delozier, Thierry
    Tubiana-Hulin, Michele
    Schneeweiss, Andreas
    Lluch, Ana
    Llombart, Antonio
    du Bois, Andreas
    Kreienberg, Rolf
    Mayordomo, Jose Ignacio
    Anton, Antonio
    Harrison, Mark
    Jones, Alison
    Carrasco, Eva
    Vaury, A. Thareau
    Frimodt-Moller, Bente
    Fumoleau, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1753 - 1760
  • [34] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [35] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
    Anders, Carey K.
    Le Rhun, Emilie
    Bachelot, Thomas Denis
    Yardley, Denise A.
    Awada, Ahmad
    Conte, Pier Franco
    Kabos, Peter
    Bear, Melissa
    Yang, Zhengyu
    Chen, Yanyun
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Frontline docetaxel (T) capecitabine M combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study.
    Chun, JH
    Lee, HG
    Lee, ES
    Kim, E
    Oh, JH
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 71S - 71S
  • [37] Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)
    Robert, Nicholas J.
    Dieras, Veronique
    Jackisch, Christian
    Srock, Stefanie
    Freudensprung, Ulrich
    Faoro, Leonardo
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2014, 74 (19)
  • [38] First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts).
    Thomssen, C.
    Pierga, J-Y
    Pritchard, K., I
    Biganzoli, L.
    Cortes-Funes, H.
    Petrakova, K.
    Kaufman, B.
    Smith, I. E.
    CANCER RESEARCH, 2009, 69 (24) : 854S - 854S
  • [39] Safety of pertuzumab (P) with trastuzumab (T) and docetaxel (D) in patients (pts) from Asia with HER2-positive metastatic breast cancer (MBC): Results from the phase III trial CLEOPATRA
    Swain, S. M.
    Im, Y-H
    Im, S-A
    Miles, D.
    Knott, A.
    Clark, E.
    Ross, G.
    Baselga, J.
    CANCER RESEARCH, 2013, 73
  • [40] First results of AVEREL, a randomized phase Ill trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) plus docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
    Gianni, L.
    Romieu, G.
    Lichinitser, M.
    Serrano, S.
    Mansutti, M.
    Pivot, X.
    Smirnova, I.
    Moliterni, A.
    Andre, F.
    Chan, A.
    Lipatov, O.
    Chan, S.
    Wardley, A.
    Greil, R.
    Provencher, L.
    Moore, N.
    Prot, S.
    Semiglazov, V.
    CANCER RESEARCH, 2011, 71
12345